

Supplementary Materials: Co-Spray Dried Nafamostat Mesylate with Lecithin and Mannitol as Respirable Microparticles for Targeted Pulmonary Delivery: Pharmacokinetics and Lung Distribution in Rats

Ji-Hyun Kang, Young-Jin Kim, Min-Seok Yang, Dae Hwan Shin, Dong-Wook Kim, Il Yeong Park and Chun-Woong Park




Figure S1. Linearity of nafamostat mesylate (NFM) HPLC analysis method validation.

Table S1. Linearity of nafamostat mesylate (NFM) HPLC analysis method validation.

Concentration (µg mL ⁻¹)	Area	Calculated Concentration (µg mL ⁻¹)	Deviation (%)
6.25	2.58	6.18	1.10
12.50	5.897	12.17	2.64
25.00	13.182	25.32	1.29
50.00	26.975	50.22	0.45
100.00	54.465	99.85	0.15
R²	0.99995		
Slope	0.55		
Intercept	-0.84		

Table S2. Accuracy of nafamostat mesylate (NFM) HPLC analysis method validation.

Sample No.	Concentration ($\mu\text{g mL}^{-1}$)	area	Founded Concentration ($\mu\text{g mL}^{-1}$)	recovery (%)
1	25.00	13.75	26.34	105.37
2	50.00	27.52	51.20	102.40
3	100.00	55.29	101.34	101.34
4	25.00	13.80	26.44	105.75
5	50.00	27.58	51.31	102.62
6	100.00	55.06	100.93	100.93
7	25.00	13.88	26.59	106.35
8	50.00	27.53	51.23	102.46
9	100.00	55.16	101.10	101.10
Average				103.15
Standard deviation				2.11
%RSD				2.05

Table S3. Precision of nafamostat mesylate (NFM) HPLC analysis method validation.

Sample No.	Concentration ($\mu\text{g mL}^{-1}$)	area
1	100	54.26
2	100	54.10
3	100	54.28
4	100	54.94
5	100	54.41
6	100	55.09
Average		54.52
Standard deviation		0.40
%RSD		0.74